Home » Stocks » AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc. (AVEO)

Stock Price: $5.83 USD -0.06 (-1.02%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
After-hours: $5.80 -0.03 (-0.52%) Oct 20, 4:32 PM

Stock Price Chart

Key Info

Market Cap 150.46M
Revenue (ttm) 28.01M
Net Income (ttm) -3.72M
Shares Out 25.81M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $5.83
Previous Close $5.89
Change ($) -0.06
Change (%) -1.02%
Day's Open 5.90
Day's Range 5.76 - 5.90
Day's Volume 128,602
52-Week Range 2.23 - 10.71

More Stats

Market Cap 150.46M
Enterprise Value 91.07M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.81M
Float 21.77M
EPS (basic) -0.23
EPS (diluted) -0.23
FCF / Share -0.45
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.11M
Short Ratio 1.72
Short % of Float 5.12%
Beta 1.40
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 5.37
PB Ratio 3.28
Revenue 28.01M
Operating Income -5.91M
Net Income -3.72M
Free Cash Flow -7.77M
Net Cash 59.39M
Net Cash / Share 2.30
Gross Margin 38.68%
Operating Margin -21.08%
Profit Margin -13.30%
FCF Margin -27.73%
ROA -6.30%
ROE -14.97%
ROIC -21.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$12.00*
(105.83% upside)
Low
7.00
Current: $5.83
High
17.00
Target: 12.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue28.805.417.582.5219.0218.121.2919.2916544.68
Revenue Growth432.35%-28.63%201.35%-86.78%4.97%1301.62%-93.3%-88.3%268.94%-
Gross Profit28.805.417.582.5219.0218.121.2919.2916544.68
Operating Income-0.37-25.36-28.81-29.39-12.43-50.45-104-11233.95-56.43
Net Income9.39-5.33-65.03-26.89-15.00-52.74-107-11430.65-58.79
Shares Outstanding15.3312.0610.596.935.575.235.094.343.972.56
Earnings Per Share0.61-1.93-6.14-3.90-2.70-10.10-21.00-26.407.40-23.00
Operating Cash Flow-2.92-25.03-19.16-31.07-18.23-54.25-84.40-10626.45-51.83
Capital Expenditures----0.011.22-12.75-3.67-9.95-2.63-1.69
Free Cash Flow-2.92-25.03-19.16-31.07-17.01-67.00-88.07-11623.82-53.51
Cash & Equivalents47.7524.4333.5323.3534.1455.30122164222141
Total Debt15.7719.0318.4814.009.4725.6319.2126.0424.1723.40
Net Cash / Debt31.985.3915.059.3524.6629.67103138198117
Assets50.6027.9450.2027.2940.5470.66146207295151
Liabilities35.7555.1690.9629.2123.3250.0676.4188.5371.5179.28
Book Value14.85-27.23-40.76-1.9217.2320.6169.9411922471.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AVEO Pharmaceuticals, Inc.
Country United States
Employees 19
CEO Michael P. Bailey

Stock Information

Ticker Symbol AVEO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AVEO
IPO Date March 12, 2010

Description

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. AVEO Pharmaceuticals, Inc. has collaboration and license agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Kirin Company AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.